zimberelimab
zimberelimab: sourced relationships with 1 company · 35 clinical trials tracked.
zimberelimab evidence translation
What we can confirm
35 tracked trials
What it means
What to watch
Prepared research question
How could zimberelimab → RCUS affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 3 study sponsors
Related indications
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Arcus Biosciences, Inc. (RCUS) Advanced Solid Tumors; Oligometastatic Prostate Cancer; Non … | Phase 3 |
Clinical Trial Registry Records (35)showing 10 most recent
PRE-surgical NEOadjuvant Sandwich Immunotherapy With HIF inhibiTion in Renal Cell Carcinoma (PRENEOSHIFT-RCC)
Primary endpoint: Tumor Size Reduction Rate
A Single-Arm, Phase II Study of Perioperative Zimberelimab + Domvanalimab and Neoadjuvant Chemotherapy in Locally Advanced, Resectable, Gastroesophageal Adenocarcinoma
Primary endpoint: Rate of Event-free Survival (EFS)
VELOCITY-HNSCC Substudy-01: A Phase 2 Study of Novel Combination Therapies in Participants With Previously Untreated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status
Primary endpoint: Objective response rate (ORR)
A First-in-Human, Phase 1 Dose Escalation and Dose Expansion Trial to Assess the Safety and Tolerability of COM503 as Monotherapy and in Combination Therapy in Participants With Advanced Solid Malignancies
Primary endpoint: To evaluate the safety profile of COM503 as monotherapy in participants with advanced malignancies.
A Phase 1 Study to Evaluate the Safety and Tolerability of GS-2121 as Monotherapy and in Combination in Adults With Advanced Solid Tumors
Primary endpoint: Parts A and B: Percentage of Participants with Adverse Events and Serious Adverse Events
A Phase 2, Open-Label, Multicenter, Randomized Study Evaluating Neoadjuvant Therapy Targeting the Adenosine Immunosuppressive Pathway in Combination With Immune Checkpoint Blockade and Radiation Therapy in Patients With Advanced PANCreatic Ductal Adenocarcinoma Who Are Candidates for Surgical Resection
Primary endpoint: Change in the number of intratumoral CD8+ T-cells
Study of Gemcitabine, Cisplatin, Quemliclustat (AB680) and Zimberelimab (AB122) During First-line Treatment of Advanced Biliary Tract Cancers (QUIC)
Primary endpoint: Estimate the progression free survival (PFS) with gemcitabine, cisplatin, quemliclustat (AB680) and zimberelimab (AB122) in patients with advanced BTCs.
A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB598 Monotherapy and Combination Therapy in Participants With Advanced Malignancies
Primary endpoint: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
A Phase 1 Study to Evaluate the Safety and Tolerability of GS-9911 as Monotherapy and in Combination With an Anti-PD-1 Monoclonal Antibody in Adults With Advanced Solid Tumors
Primary endpoint: Percentage of Participants With Treatment-emergent Adverse Events
Phase II Single Arm Study Testing SBRT, Adenosine Signaling Modulation (AB680, AB928), and Immune Checkpoint Inhibition (AB122) for Men With Hormone Sensitive Oligometastatic Prostate Cancer
Primary endpoint: Biochemical recurrence-free survival at 12-months
Frequently asked questions
Which companies have sourced relationships with zimberelimab?
zimberelimab has dated SEC/FDA relationship records for Arcus Biosciences, Inc..
How many clinical trials involve zimberelimab?
BioSniper tracks 35 clinical trials involving zimberelimab.